TFG Asset Management’s Karyopharm Therapeutics KPTI Stock Holding History

TFG Asset Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.45M	Buy	250,300 +200,300	+401%	+$1.74M	0.39%	33
2026 Q1	$279K	Buy	+50,000	New	+$381K	0.05%	36

Other funds holding KPTI

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GCM

Ghisallo Capital Management Boston, Massachusetts $5.1B AUM 39.12% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

TFG Asset Management's KPTI Position: Q2 2026 in Review

TFG Asset Management sold out of Karyopharm Therapeutics (KPTI) in Q2 2026, closing a stake of 52,984 shares — an estimated $460K sold.

TFG Asset Management first reported a position in KPTI in Q1 2026 and held it in 1 quarter. The position peaked at $295K in Q1 2026. 63 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

TFG Asset Management reported no remaining Karyopharm Therapeutics position as of Q2 2026 after selling out during the quarter.
TFG Asset Management sold 52,984 Karyopharm Therapeutics shares in Q2 2026, an estimated $460K.
TFG Asset Management first reported a position in Karyopharm Therapeutics in Q1 2026 and held it in 1 quarter.
TFG Asset Management's Karyopharm Therapeutics position peaked at $295K in Q1 2026.
63 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on TFG Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.